Results 51 to 60 of about 93,319 (307)
Zonated osteochondral assembloid implants are engineered through scaffold‐free spatial assembly of induced pluripotent stem cell (iPSC)‐derived chondrocyte organoids and periosteum‐derived osteogenic organoids. Implanted into full‐thickness rat osteochondral defects, they promote hyaline‐like cartilage repair, support subchondral bone formation with ...
Liuqi Peng +3 more
wiley +1 more source
Can Epirubicin Be Used in Laryngology Practice Like Mitomycin? An Experimental and Pioneering Study [PDF]
Introduction: Epirubicin and mitomycin-C share similar mechanisms of action, with both exhibiting antiproliferative effects by inhibiting DNA and protein synthesis.
Erdem Koroglu +5 more
doaj +1 more source
Background and aim: To find if intra-operative local injection of Mitomycin-C after internal Urethrotomy in patients with urethral stricture can improve the outcome of surgery.
Jalil Hosseini +5 more
doaj +1 more source
UBR2 of the N-end rule pathway is required for chromosome stability via histone ubiquitylation in spermatocytes and somatic cells [PDF]
The N-end rule pathway is a proteolytic system in which its recognition components (N-recognins) recognize destabilizing N-terminal residues of short-lived proteins as an essential element of specific degrons, called N-degrons.
An, JY +12 more
core +1 more source
Colicin Factors and Mitomycin-C [PDF]
SUMMARY: Mitomycin-C increased the titres of all of nine colicins tested, regardless of whether the colicin factor comprised a sex factor.
K G, Hardy, G G, Meynell
openaire +2 more sources
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance +17 more
wiley +1 more source
EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal +75 more
core +1 more source
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
Generation of virus-specific cytotoxic T cells in vitro I. Induction conditions of primary and secondary Sendai virus-specific cytotoxic T cells [PDF]
H-2-restricted cytotoxic T cells specific for Sendai virus were generated in vitro in a primary response from normal mouse lymphocytes cultured in the presence of infective as well as inactivated Sendai virus. Antigen-presenting cells of different origin,
Andersson +41 more
core +1 more source
We report a new thiolate‐reactive α,α‐gem‐dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti‐inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. RNA‐seq illuminated detailed transcriptional profiles, and chemical reactions with cysteine‐containing compounds ...
Beau R. Brummel +16 more
wiley +1 more source

